BIOMAT Database Logo BIOMAT Database Logo

Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W 135: clinical and serological evaluation. 1982

J Armand, and F Arminjon, and M C Mynard, and C Lafaix

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009345 Neisseria meningitidis A species of gram-negative, aerobic BACTERIA. It is a commensal and pathogen only of humans, and can be carried asymptomatically in the NASOPHARYNX. When found in cerebrospinal fluid it is the causative agent of cerebrospinal meningitis (MENINGITIS, MENINGOCOCCAL). It is also found in venereal discharges and blood. There are at least 13 serogroups based on antigenic differences in the capsular polysaccharides; the ones causing most meningitis infections being A, B, C, Y, and W-135. Each serogroup can be further classified by serotype, serosubtype, and immunotype. Diplokokkus intracellularis meningitidis,Meningococcus,Micrococcus intracellularis,Micrococcus meningitidis,Micrococcus meningitidis cerebrospinalis,Neisseria weichselbaumii
D011135 Polysaccharides, Bacterial Polysaccharides found in bacteria and in capsules thereof. Bacterial Polysaccharides
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D001428 Bacterial Vaccines Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease. Bacterial Vaccine,Bacterin,Vaccine, Bacterial,Vaccines, Bacterial

Related Publications

J Armand, and F Arminjon, and M C Mynard, and C Lafaix
Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, and Y.
January 1978, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
J Armand, and F Arminjon, and M C Mynard, and C Lafaix
Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135.
January 1982, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
J Armand, and F Arminjon, and M C Mynard, and C Lafaix
Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.
October 2007, Archives of disease in childhood,
J Armand, and F Arminjon, and M C Mynard, and C Lafaix
Meningococcal group A, C, Y and W-135 conjugate vaccine.
June 2010, Nature reviews. Drug discovery,
J Armand, and F Arminjon, and M C Mynard, and C Lafaix
Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents.
August 2019, Vaccine,
J Armand, and F Arminjon, and M C Mynard, and C Lafaix
Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults.
February 2011, Human vaccines,
J Armand, and F Arminjon, and M C Mynard, and C Lafaix
The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine.
August 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
J Armand, and F Arminjon, and M C Mynard, and C Lafaix
The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiority study.
July 2012, Human vaccines & immunotherapeutics,
J Armand, and F Arminjon, and M C Mynard, and C Lafaix
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.
January 2014, Infection and drug resistance,
J Armand, and F Arminjon, and M C Mynard, and C Lafaix
Meningococcal vaccine against serogroups A, C, Y and W-135: new preparation. Encouraging immunogenicity studies.
April 2002, Prescrire international,
Copied contents to your clipboard!